PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.11
D/E ratio at 50-90% of Drug Manufacturers - Specialty & Generic median of 0.18. Peter Lynch would verify if this conservative capital structure supports growth opportunities.
23.22
Dangerously high net debt exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.33. Michael Burry would check for debt covenant compliance and refinancing risks.
-3.72
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
2.47
Current ratio near Drug Manufacturers - Specialty & Generic median of 2.35. David Dodd would examine if industry-standard liquidity is appropriate given business model.
68.48%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.28%. Michael Burry would check for aggressive accounting and hidden risks.